Possible increased risk of pulmonary edema in patients with hepatorenal syndrome on adding octreotide to albumin / noradrenaline therapies

Saudi J Kidney Dis Transpl. 2007 Jun;18(2):261.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Adrenergic alpha-Agonists / adverse effects*
  • Adrenergic alpha-Agonists / therapeutic use
  • Albumins / adverse effects*
  • Albumins / therapeutic use
  • Antineoplastic Agents, Hormonal / adverse effects*
  • Antineoplastic Agents, Hormonal / therapeutic use
  • Drug Therapy, Combination
  • Fatal Outcome
  • Hepatorenal Syndrome / drug therapy*
  • Humans
  • Norepinephrine / adverse effects*
  • Norepinephrine / therapeutic use
  • Octreotide / adverse effects*
  • Octreotide / therapeutic use
  • Pulmonary Edema / chemically induced*
  • Risk Factors

Substances

  • Adrenergic alpha-Agonists
  • Albumins
  • Antineoplastic Agents, Hormonal
  • Octreotide
  • Norepinephrine